1. Participant is aged 18 to 65 years, inclusive, at screening
2. Participant is capable of providing informed consent
3. Participant has a primary diagnosis of schizophrenia, established by a comprehensive psychiatric evaluation based on the DSM-5 (American Psychiatric Association 2013) criteria and confirmed by Structured Clinical Interview for DSM-5 Clinical Trials version (SCID-5-CT)
4. Participant is willing and able to be confined to an inpatient setting for the study duration (except for the follow-up period), follow instructions, and comply with the protocol requirements
5. Participant is experiencing an acute exacerbation or relapse of psychotic symptoms, with onset less than 2 months before screening
1. The participant requires hospitalization for this acute exacerbation or relapse of symptoms
2. If already an inpatient at screening, has been hospitalized for less than 2 weeks for the current exacerbation at the time of screening
6. Positive and Negative Syndrome Scale total score between 80 and 120, inclusive, at screening a. Score of ≥ 4 (moderate or greater) for ≥ 2 of the following Positive Scale (P) items:
i. Item 1 (P1; delusions)
ii. Item 2 (P2; conceptual disorganization)
iii. Item 3 (P3; hallucinatory behavior)
iv. Item 6 (P6; suspiciousness/persecution)
You may not be if
1. Any primary DSM-5 disorder other than schizophrenia within 12 months before screening (confirmed using Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) at screening)
2. History of treatment resistance to antipsychotic medications defined as inadequate response to two adequate courses of pharmacotherapy or previous clozapine treatment for treatment-resistant schizophrenia
3. Participants who need to be treated with drugs that are known to be moderate and strong CYP3A4 inhibitors and inducers will be excluded
4. Participants taking a long-acting injectable antipsychotic could not have received a dose of medication in the last 12 weeks (24 weeks for INVEGA TRINZA®) before baseline
Clareo Health | Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
